$MCRB News

On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate

Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study

Seres Therapeutics Posts Early Data for Cancer Therapy Complication

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript

Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis

HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone Payments